INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) recipients have a high risk for invasive pneumococcal disease, [1] [2] [3] and immunization is the main preventative strategy. 4, 5 The European Society for Blood and Marrow Transplantation (EBMT) trial Infectious Diseases Working Party 1 (IDWP01) showed that an early vaccination with three doses of the 7-valent pneumococcal conjugate vaccine (PCV7) given from 3 months after transplant and assessed on the immune response to all seven serotypes of PCV7 1 month after the third dose was not inferior to the same schedule started from 9 months after transplant. 6, 7 Furthermore, a dose of 23-valent polysaccharide vaccine (PPV23) given at 12 months after transplant pneumococcal not only induce an immune response to the PCV7 serotypes in 42% of the previously non-responder patients but also extends the serotype coverage to the PPV23-specific serotypes in 80% of them. 6 On the basis of this study [6] [7] [8] and others 9, 10 showing the immunogenicity of the PCV7 during the first year of transplant, the current international guidelines recommend three doses of PCV13 -which substituted to PCV7 in 2010 on the basis of pediatric studies 11 -at 1-month interval, to be started from 3 to 6 months after transplant, followed at 12 months after transplant by either a dose of PPV23 if the patient has no chronic GVHD or an additional dose of PCV13 in case of chronic GVHD. 4, 5 In the IDWP01 trial, we followed the patients until 24 months after transplant, which is, to our knowledge, the latest date so far assessed in a controlled trial for durability of the antipneumococcal immune response in HSCT recipients. At 24 months, the patients who had been vaccinated early after transplant had significantly lower levels of antibodies against both PCV7 and PPV23 serotypes than the patients who had been vaccinated late. However, due to the lack of data on long-term persistence of the immune response, the more recent international guidelines do not give any recommendation for further boosts later than 12 months after transplant. 5 In order to assess the durability of the immune response several years after the primary vaccination schedule, we assessed the IgG levels and the opsonocytophagocytic (OPA) titers against all the seven serotypes of PCV7 and against two of the specific PPV23 serotypes-not included in the conjugate-in a subgroup of long-term survivors included in the IDWP01 trial 10 years ago. Our results give indications on the need for boost doses after the initial series of pneumococcal vaccines.
MATERIALS AND METHODS

Study design
Between 2001 and 2004, the IDWP of the EBMT ran a prospective, randomized trial on antipneumococcal vaccination after HSCT. 7 One hundred and fifty-eight allogeneic HSCT recipients at 13 centers in 7 countries were recruited in the IDWP01 trial. The patients were included at 3 months after transplant, and randomized to receive three doses of PCV7 with 1-month intervals, either starting at 3 months (early group) or at 9 months after HSCT (late group), followed by a dose of PPV23 6 months later. The immune response was measured at baseline, 1 month after the second dose of PCV7, 1 month after the third dose of PCV7 and before and after the PPV23 dose. All patients were followed up to 24 months or death, whichever occurred first. Eighty-six surviving patients were assessed at 24 months after transplant (last study visit) for specific IgG against the seven serotypes of PCV7 and against pn1 and pn5. 6 The subsequent (after 24 months) vaccination program was left to the initiative of the centers.
The present study was run between March 2012 and December 2013 in the three best recruiting centers of the IDWP01 study: Créteil, Paris SaintLouis, and Stockholm, which initially recruited 32, 21 and 18 patients in the IDWP01 trial, respectively. For the present follow-up study, the goal was to solicit all the surviving patients still followed in the centers. All patients included had a serum sample to assess the residual immune response.
This study was approved by the Comité de Protection des PersonnesIle de France IX and by the Ethical Review Board of Stockholm. A written informed consent was obtained from all patients.
Among the 71 patients initially included in the IDWP01 trial in the three centers, 41 were still evaluable at 24 months after HSCT for immunogenicity. Among these 41 patients, 7 died between 24 months post transplant and the time of the present study from myocardial infarction (n = 1), hematological relapse (n = 2), cirrhosis (n = 1), lung fibrosis (n = 1), prostate cancer (n = 1) and GVHD complicated by infections (n = 1). Three patients were lost to follow-up, mainly because of living far away from the transplant center. One patient was not solicited because of current therapy for refractory larynx carcinoma. Thus, finally 30 patients were eligible.
Sera collection and antibody measurements
After patient consent, venous blood samples were obtained and labeled using the code numbers of IDWP01. Sera were immediately frozen at − 20°C on site and shipped frozen to the US Pfizer Laboratories (Pearl River, NY, USA). Specific serum IgG levels to the seven vaccine serotypes (pn4, pn6B, pn9 V, pn14, pn18C, pn19 F, pn23 F), and to pn1 and pn5 as markers of the immune response to PPV23, were determined using a double-absorbent serotype-specific anti-pneumococcal capsular polysaccharide ELISA, 12 and the results were expressed as μg/mL using the standard reference serum 89-SF, as done in the IDWP01 study. The quantification limit was 0.01 μg/mL for all serotypes. All serum samples were bar-coded and tested blindly by qualified laboratory personnel. Additionally, the OPA titers were assessed for each PCV7 serotype, pn1 and pn5 by an OPA assay as previously described.
Statistical analyses
The objectives of the study were:
(a) to assess the immune response to Streptococcus pneumoniae around 10 years after SCT in the cohort of the IDWP01 patients on the basis of the geometric mean concentrations (GMC) of serum IgG antibodies against the seven antigens of the PCV7 and the two antigens (pn1 and 5) of the PPV23. (b) b) reassess the other parameters assessed at 24 months in the cohort (percentage of patients with all PCV7 antibodies ⩾ 0.15 and ⩾ 0.50 μg/ mL). These parameters were compared with the same parameters assessed 24 months after transplant.
The percentage of responders was defined as those having an antibody titer ⩾ 0.15 μg/mL or ⩾ 0.5 μg/mL to all the seven serotypes present in the PCV7 vaccine. Additionally, the response to the pn1 and pn5 antigens were also assessed according to the same cutoffs. The proportion of response was compared with the one at 24 months after transplant by Chi-square test or Fisher's exact test when appropriate.
Comparisons of GMCs at 24 months vs last follow-up were performed using non-parametric Wilcoxon's test for paired data. Correlations between OPA and antibody titers were performed using non-parametric Spearman's test.
RESULTS
Patients
Thirty patients were included (Table 1) . They were between 8 and 11 years after a myeloablative conditioned transplant, that is, 6-9 years after the last study visit (24 months) in the IDWP01 trial. No patient had received a second transplant. Only two patients had leukemia relapse in the meantime: one 4.5 and the second 5 years after transplant. Both had received DLIs and imatinib and were in CR at study time. No patient had received IVIG or rituximab since 24 months post transplant. The Karnofsky score was 100% in 25/30 patients. Chronic GVHD was seen in 23% (7/30) but was limited in most of them, only treated with topical medications. Only one patient had symptoms of chronic GVHD and was receiving low-dose CYA at the time of the study. Twelve patients were receiving prophylactic antibacterials, mostly oral penicillin. Only one patient with chronic GVHD and under oral penicillin prophylaxis had developed a pneumococcal infection after 24 months post transplant: this patient got an acute arthritis due to S. pneumoniae serotype 19 F, 39 months after transplant. This patient had not responded to the initial vaccination program. Eleven of these 30 patients (37%) had received a PPV23 dose, 4-8.5 years after transplant and 2-6 years before the present study, according to the local clinician's decision and, in two patients, on the basis of low antipneumococcal antibody serum levels on local assessment.
Response rates
The rates of persistent response to the seven antigens of PCV7 were 65.5% for the antibody cutoff of 0.15 μg/mL and 40% for the cutoff of 0.50 μg/mL (Table 2) . Compared with the response rate at 24 months, these rates were not significantly decreased. The response rates for pn1 and pn5 were also not significantly decreased, whatever the cutoff used.
The evolution of the GMCs of the different serotypes from baseline (time 1) in IDWP01 study (before the first PCV7 dose) to the time of the present study (time 7) is shown in Figure 1 . When 
Factors influencing the persistence of the response Among the factors that could influence the persistence of the response (recipient age, donor age, donor type (matched related vs other), source of stem cells (BM vs peripheral blood), GVHD at 24 months and administration of a PPV23 dose between 24 months and study time), none influenced the maintenance of the response, whatever the antibody cutoff considered ( Table 3 ). The only parameter influencing the response was the timing of the initial vaccination: the response was significantly better in patients of the late group than in the patients of the early group, both when considering the cutoff of 0.15 μg/mL (14/16 vs 5/13, P = 0.02) or the cutoff of 0.50 μg/mL (10/17 vs 2/13, P = 0.03).
Effect of an additional dose of PPV23 Among the 11 patients who received a PPV23 dose between 4 and 8.5 years after transplant, the three patients who were not responders (antibody levels against the nine antigens o0.15 μg/ mL) at 24 months remained in the same situation at time of the present study, performed 39, 40 and 72 months after the PPV23 dose, respectively. For three patients, the response at 24 months was unknown, and 10 years later, two of them had antibody levels 40.5 μg/mL for the nine antigens. Two patients had their antibody levels on the nine antigens between 0.15 and 0.5 μg/ mL at 24 months; one kept the same profile and the second had antibody levels 40.5 μg/mL 10 years later. Three patients had antibody levels 40.5 μg/mL for the nine antigens at 24 months; two kept the same profile, and one was between 0.15 and 0.5 μg/ mL 10 years later.
Finally, when just considering the cutoff of 0.15 μg/mL for the nine vaccine antigens, 7 out of the 11 revaccinated patients were above this cutoff at the time of the present study, and none of the non-responders at 24 months did further respond to the PPV23 dose.
OPA assays and correlation with the pneumococcal IgG ELISA The OPA tests correlated significantly with the antibody levels of all serotypes, except for serotype pn5. No OPA assessment was performed at 24 months after transplant in the IDWP01 trial, and therefore no comparison with previous OPA tests was possible.
DISCUSSION
Our study shows that after an initial vaccination program of three doses of conjugate antipneumococcal vaccine, followed by one dose of PPV23 during the first 18 months after transplant, as presently recommended in published guidelines, 4,5 the specific antibody levels were generally well maintained at 8-11 years after transplant, with consistent OPA titers. However, the evolution of the antibody levels ( Figure 1 ) were in fact very serotypedependent. We know from the IDWP01 trial that the patients vaccinated with three doses of PCV7 from 3 months after transplant, followed by a dose of PPV23 at 12 months, had significantly lower antibody levels at 24 months than the patients vaccinated from 9 months and receiving the PPV23 at 18 months after transplant. 6 This is probably related to a better immune recovery at 9 months, rather than at 3 months after transplant, and also to the fact that in the late group the time of administration of the PPV23 dose (18 months) was closer to the antibody assessment of 24 months. 6, 7 Because of the noninferiority of the early compared with late immunization when assessed 1 month after the three PCV doses, this finding does not change the recommendation of early vaccination with PCV13 as currently recommended. 4, 5 Despite that there were no significant decreases in the proportion of patients with 'protective' antibody levels during follow-up, a significant proportion of our patients have, 10 years later, antibody levels o0.50 μg/mL, including 9 of the 17 patients initially vaccinated with a late program, and should be offered a boost immunization.
Few data exist about the long-term durability of the immune response after antipneumococcal vaccination. In older adults, after being given one or two doses of PPV23, despite that the antibody levels decreased, the levels still exceed the prevaccination levels 10 years later. 13 In kidney transplant patients vaccinated a mean of 1.2 years after transplant with either one dose of PCV7 or one dose of PPV23, the specific antibody levels had significantly decreased 3 years later, especially for pn4 and pn9V, and the durability of the response did not depend on the type of the vaccine but only on the level of the initial response. 14 In HSCT patients, due to the lack of data in the literature, the more recent guidelines do not give any recommendation on antipneumococcal immunization after 12 months posttransplant. 5 Our study is the first with a long follow-up of an homogeneous cohort of patients vaccinated 10 years ago according to the current guidelines. Surprisingly, the 11 patients who received an additional dose of PPV23 between 4 and 8.5 years after transplant do not seem to have benefited from this vaccine when compared with the not-revaccinated patients. At least, the three patients who were not responders at 24 months were not better protected 10 years later, and one of the responders at 24 months had a decreased antibody level despite an additional dose of PPV23. Although our results do not indicate the optimal booster program in these patients, they strongly suggest that the effect of one dose of PPV23 several years after transplant is probably lower than expected, even in a population with a low rate of chronic GVHD and several years after transplant. Knowing the benefit of the conjugation in immunocompromised patients, 15 ,16 a better response might have been expected from a boost with the conjugate. However, due to the possibility of hyporesponsiveness when the conjugate is given after the PPV23, [17] [18] [19] this should be prospectively explored. Additionally, some patients do not respond to the initial schedule of vaccination-roughly 20% in the IDWP01 study-and although mostly explained by GVHD or deep hypogammaglobulinema, there might be unexplained factors for the non-response.
We recognize the limits of our study. First, we limited the study to the main recruiting centers of the initial study for practical reasons resulting in a selection of only 30 patients for this study. However, we consider these patients, with a low rate of GVHD, as representative of the whole cohort of survivors 10 years later. Second, the administration of an additional dose of PPV23 after 24 months was not randomized, did concern only 11 patients and its efficacy was assessed only 2-6 years later. This limits the conclusions we may draw about the optimal boosting program after 24 months post transplant.
In conclusion, our data show that even in long-term HSCT survivors with no or limited GVHD vaccinated against S. pneumoniae according to the current guidelines, the specific immunity is not fully maintained a decade later but with a wide variability from one serotype to another. Individual assessments of vaccine-serotype antibodies, although not performed routinely in most countries, could help in identifying the non-responders to the initial vaccine program (14-18 months) and eventually later for deciding to revaccinate. In our patients, there is no evidence that an additional dose of PPV23 given between 2 and 10 years was beneficial, neither to induce a response in patients who were not responders at 24 months nor to maintain the response of those who were already responders. The optimal schedule of antipneumococcal vaccination in HSCT recipients after 12 months remains to be established and deserve prospective assessment. Pending the results of further studies, the rule of preferring a conjugate in patients with chronic GVHD and the polysaccharide vaccine in patients without GVHD seem reasonable.
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